Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

Genome Biology

Volumn 9, Issue 1, 2008, Pages

  Welsch, Christoph ^a,b,c   Domingues, Francisco S ^a   Susser, Simone ^b,c   Antes, Iris ^a   Hartmann, Christoph ^a   Mayr, Gabriele ^a   Schlicker, Andreas ^b   Sarrazin, Christoph ^b,c   Albrecht, Mario ^a   Zeuzem, Stefan ^b,c   Lengauer, Thomas ^a  

^a MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; NS3 4A PROTEASE; PROTEINASE; TELAPREVIR; ANTIVIRUS AGENT; LIGAND; NS3 PROTEIN, HEPATITIS C VIRUS; OLIGOPEPTIDE; SERINE PROTEINASE; VIRUS PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PROTEIN STRUCTURE; REPLICON; SEQUENCE ALIGNMENT; VIRUS MUTANT; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; BINDING SITE; DRUG EFFECT; ENZYMOLOGY; GENETICS; MISSENSE MUTATION; PROTEIN BINDING;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; BINDING SITES; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HUMANS; LIGANDS; MOLECULAR DYNAMICS SIMULATION; MUTATION, MISSENSE; OLIGOPEPTIDES; PROTEIN BINDING; SERINE ENDOPEPTIDASES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 46249102168     PISSN: 14747596     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/gb-2008-9-1-r16     Document Type: Article

References (61)

1. Fried MW Shiffman ML Reddy KR Smith C Marinos G Gonçales FL Jr Häussinger D Diago M Carosi G Dhumeaux D Craxi A Lin A Hoffman J Yu J Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982. 10.1056/NEJMoa020047 12324553
2. Hadziyannis SJ Sette H Jr Morgan TR Balan V Diago M Marcellin P Ramadori G Bodenheimer H Jr Bernstein D Rizzetto M Zeuzem S Pockros PJ Lin A Ackrill AM PEGASYS International Study Group Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355. 14996676
3. Manns MP McHutchison JG Gordon SC Rustgi VK Shiffman M Reindollar R Goodman ZD Koury K Ling M Albrecht JK Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001, 358:958-965. 10.1016/S0140-6736(01)06102-5 11583749
4. Beyer BM Zhang R Hong Z Madison V Malcolm BA Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity. Proteins 2001, 43:82-88. 10.1002/ 1097-0134(20010501)43:2<82::AID-PROT1020>3.0.CO;2-4 11276078
5. Bogen SL Arasappan A Bennett F Chen K Jao E Liu YT Lovey RG Venkatraman S Pan W Parekh T Pike RE Ruan S Liu R Baroudy B Agrawal S Chase R Ingravallo P Pichardo J Prongay A Brisson J-M Hsieh TY Cheng K-C Kemp SJ Levy OE Lim-Wilby M Tamura SY Saksena AK Girijavallabhan V Njoroge FG Discovery of SCH446211 (SCH6): A new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J Med Chem 2006, 49:2750-2757. 10.1021/jm060077j 16640336
6. Lamarre D Anderson PC Bailey M Beaulieu P Bolger G Bonneau P Bos M Cameron DR Cartier M Cordingley MG Faucher A-M Goudreau N Kawai SH Kukolj G Lagacé L LaPlante SR Narjes H Poupart M-A Rancourt J Sentjens RE St George R Simoneau B Steinmann G Thibeault D Tsantrizos YS Weldon SM Yong C-L Llinàs-Brunet M An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189. 10.1038/nature02099 14578911
7. Lin C Kwong AD Perni RB Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006, 6:3-16. 16787300
8. Malcolm BA Liu R Lahser F Agrawal S Belanger B Butkiewicz N Chase R Gheyas F Hart A Hesk D Ingravallo P Jiang C Kong R Lu J Pichardo J Prongay A Skelton A Tong X Venkatraman S Xia E Girijavallabhan V Njoroge FG SCH 50 a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 3034, 50:1013-1020. 10.1128/AAC.50.3.1013-1020.2006
9. Barbato G Cicero DO Nardi MC Steinkuhler C Cortese R De Francesco R Bazzo R The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J Mol Biol 1999, 289:371-384. 10.1006/jmbi.1999.2745 10366511
10. McCoy MA Senior MM Gesell JJ Ramanathan L Wyss DF Solution structure and dynamics of the single-chain hepatitis C virus NS3 protease NS4A cofactor complex. J Mol Biol 2001, 305:1099-1110. 10.1006/jmbi.2000.4365 11162117
11. Yan Y Li Y Munshi S Sardana V Cole JL Sardana M Steinkuehler C Tomei L De Francesco R Kuo LC Chen Z Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 1998, 7:837-847. 2143993 9568891
12. Di Marco S Rizzi M Volpari C Walsh MA Narjes F Colarusso S De Francesco R Matassa VG Sollazzo M Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J Biol Chem 2000, 275:7152-7157. 10.1074/jbc.275.10.7152 10702283
13. Kouranov A Xie L de la Cruz J Chen L Westbrook J Bourne PE Berman HM The RCSB PDB information portal for structural genomics. Nucleic Acids Res 2006, 34:D302-305. 1347482 16381872 10.1093/nar/gkj120
14. The RCSB Protein Data Bank http://www.rcsb.org/pdb/home/home.do
15. Steinkuhler C Koch U Narjes F Matassa VG Hepatitis C virus protease inhibitors: Current progress and future challenges. Curr Med Chem 2001, 8:919-932. 11375758
16. Herrmann E Zeuzem S Sarrazin C Hinrichsen H Benhamou Y Manns MP Reiser M Reesink H Calleja JL Forns X Steinmann GG Nehmiz G Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061. Antivir Ther 2006, 11:371-376. 16759054
17. Hinrichsen H Benhamou Y Wedemeyer H Reiser M Sentjens RE Calleja JL Forns X Erhardt A Cronlein J Chaves RL Yong CL Nehmiz G Steinmann GG Short-term antiviral efficacy of BILN a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2061, 127:1347-1355. 10.1053/j.gastro.2004.08.002
18. Reesink HW Zeuzem S Weegink CJ Forestier N van Vliet A van de Wetering de Rooij J McNair L Purdy S Kauffman R Alam J Jansen PL Rapid decline of viral RNA in hepatitis C patients treated with VX-950: A phase Ib, placebo-controlled, randomized study. Gastroenterology 2006, 131:997-1002. 10.1053/j.gastro.2006.07.013 17030169
19. Sarrazin C Kieffer TL Bartels D Hanzelka B Muh U Welker M Wincheringer D Zhou Y Chu HM Lin C Weegink C Reesink H Zeuzem S Kwong AD Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767-1777. 10.1053/j.gastro.2007.02.037 17484874
20. Zhou Y Muh U Hanzelka BL Bartels DJ Wei Y Rao BG Brennan DL Tigges AM Swenson L Kwong AD Lin C Phenotypic and structural analyses of HCV NS3 protease ARG155 variants: Sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007, 282:22619-22628. 10.1074/ jbc.M610207200 17556358
21. Sarrazin C Rouzier R Wagner F Forestier N Larrey D Gupta SK Hussain M Shah A Cutler D Zhang J Zeuzem S SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007, 132:1270-1278. 10.1053/ j.gastro.2007.01.041 17408662
22. Tong X Chase R Skelton A Chen T Wright-Minogue J Malcolm BA Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006, 70:28-38. 10.1016/j.antiviral.2005.12.003 16448708
23. Perni RB Britt SD Court JC Courtney LF Deininger DD Farmer LJ Gates CA Harbeson SL Kim JL Landro JA Levin RB Luong Y-P O'Malley ET Pitlik J Govinda Rao B Schairer WC Thomson JA Tung RD Van Drie JH Wei Y Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants. Bioorg Med Chem Lett 2003, 13:4059-4063. 10.1016/ j.bmcl.2003.08.050 14592508
24. Perni RB Farmer LJ Cottrell KM Court JJ Courtney LF Deininger DD Gates CA Harbeson SL Kim JL Lin C Lin K Luong YP Maxwell JP Murcko MA Pitlik J Rao BG Schairer WC Tung RD Van Drie JH Wilson K Thomson JA Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants. Bioorg Med Chem Lett 2004, 14:1939-1942. 10.1016/j.bmcl.2004.01.078 15050632
25. Perni RB Pitlik J Britt SD Court JJ Courtney LF Deininger DD Farmer LJ Gates CA Harbeson SL Levin RB Lin C Lin K Moon Y-C Luong Y-P O'Malley ET Govinda Rao B Thomson JA Tung RD Van Drie JH Wei Y Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization. Bioorg Med Chem Lett 2004, 14:1441-1446. 10.1016/j.bmcl.2004.01.022 15006379
26. Kieffer TL Sarrazin C Miller J Traver S Zhou Y Bartels D Hanzelka B Muh U Lin C Reesink H Kwong A Zeuzem S Combination of telaprevir (VX-950) and PEG-IFN-alfa suppresses both wild-type virus and resistance variants in HCV genotype 1-infected patients in a 14-day phase Ib study. Hepatology 2006, 44:222A-223A.
27. Chu HM Zhou Y Bartels DJ Khunvichai A Rao BG Kwong AD Lin C Telaprevir (VX-950)-resistant variants exhibit reduced replication capacity compared to wild-type HCV in vivo and in vitro. J Hepatol 2007, 46:S230-S231. 10.1016/S0168-8278(07)62207-7
28. Zhou Y Muh U Bartels D Hanzelka B Rao G Kieffer TL Kwong AD Lin C In vitro characterization of telaprevir (VX-950) NS3 protease variants. Hepatology 2006, 44:221A.
29. Venkatraman S Njoroge FG Wu W Girijavallabhan V Prongay AJ Butkiewicz N Pichardo J Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid. Bioorg Med Chem Lett 2006, 16:1628-1632. 10.1016/j.bmcl.2005.12.046 16413182
30. Yi M Tong X Skelton A Chase R Chen T Prongay A Bogen SL Saksena AK Njoroge FG Veselenak RL Pyles RB Bourne N Malcolm BA Lemon SM Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2006, 281:8205-8215. 10.1074/ jbc.M510246200 16352601
31. Bostrom J Hogner A Schmitt S Do structurally similar ligands bind in a similar fashion? J Med Chem 2006, 49:6716-6725. 10.1021/jm060167o 17154502
32. Slater MJ Amphlett EM Andrews DM Bamborough P Carey SJ Johnson MR Jones PS Mills G Parry NR Somers DO Stewart AJ Skarzynski T Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease. Org Lett 2003, 5:4627-4630. 10.1021/ol035826v 14627400
33. Hartmann C Antes I Lengauer T IRECS: A new algorithm for the selection of most probable ensembles of side-chain conformations in protein models. Protein Sci 2007, 16:1294-1307. 10.1110/ps.062658307 17567749
34. Simmonds P Bukh J Combet C Deléage G Enomoto N Feinstone S Halfon P Inchauspé G Kuiken C Maertens G Mizokami M Murphy DG Okamoto H Pawlotsky JM Penin F Sablon E Shin-I T Stuyver LJ Thiel HJ Viazov S Weiner AJ Widell A Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42:962-973. 10.1002/hep.20819 16149085
35. Domingues FS Rahnenführer J Lengauer T Conformational analysis of alternative protein structures. Bioinformatics 2007, 23:3131-3138. 10.1093/bioinformatics/btm499 17933849
36. PyMOL http://pymol.sourceforge.net/
37. Chimera http://www.cgl.ucsf.edu/chimera/
38. Stahl M Rarey M Detailed analysis of scoring functions for virtual screening. J Med Chem 2001, 44:1035-1042. 10.1021/jm0003992 11297450
39. Rarey M Kramer B Lengauer T Klebe G A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996, 261:470-489. 10.1006/jmbi.1996.0477 8780787
40. MDL ISIS/Draw http://www.mdl.com/products/framework/isis_draw/index.jsp
41. MOE Molecular Operating Environment http://www.chemcomp.com/
42. Hooft RW Sander C Vriend G Positioning hydrogen atoms by optimizing hydrogen-bond networks in protein structures. Proteins 1996 26 363 376 10.1002/(SICI)1097-0134(199612)26:4<363::AID-PROT1>3.0.CO;2-D 8990493
43. WHAT IF Web Interface http://swift.cmbi.kun.nl/WIWWWI/
44. Cytoscape http://www.cytoscape.org/
45. Wallace AC Laskowski RA Thornton JM LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995, 8:127-134. 10.1093/protein/8.2.127 7630882
46. Assenov Y Ramirez F Schelhorn SE Lengauer T Albrecht M Computing topological parameters of biological networks. Bioinformatics 2008, 24:282-284. 10.1093/bioinformatics/btm554 18006545
47. NetworkAnalyzer http://med.bioinf.mpi-inf.mpg.de/networkanalyzer/
48. Lindahl E Hess B van der Spoel D GROMACS 3.0: A package for molecular simulation and trajectory analysis. J Mol Mod 2001, 7:306-317.
49. Scott WRP Hunenberger PH Tironi IG Mark AE Billeter SR Fennen J Torda AE Huber T Krüger P van Gunsteren WF The GROMOS biomolecular simulation program package. J Phys Chem A 1999, 103:3596-3607. 10.1021/ jp984217f
50. Hess B Bekker H Berendsen HJC Fraaije JGEM LINCS: A linear constraint solver for molecular simulations. J Comput Chem 1997, 18:1463-1472. 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
51. Berendsen HJC Postma JPM van Gunsteren WF Hermans J Intermolecular Forces Dordrecht: Reidel 1981.
52. Humphrey W Dalke A Schulten K VMD: Visual molecular dynamics. J Mol Graph 1996, 14:33- 38. 10.1016/0263-7855(96)00018-5 8744570
53. Wu CH Apweiler R Bairoch A Natale DA Barker WC Boeckmann B Ferro S Gasteiger E Huang H Lopez R Magrane M Martin MJ Mazumder R O'Donovan C Redaschi N Suzek B The Universal Protein Resource (UniProt): An expanding universe of protein information. Nucleic Acids Res 2006, 34:D187-191. 1347523 16381842 10.1093/nar/gkj161
54. UniProt: The Universal Protein Resource http://www.expasy.uniprot.org/
55. Edgar RC MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004, 32:1792-1797. 390337 15034147 10.1093/nar/gkh340
56. Galtier N Gouy M Gautier C SEAVIEW and PHYLO_WIN: Two graphic tools for sequence alignment and molecular phylogeny. Comput Appl Biosci 1996, 12:543-548. 9021275
57. Kabsch W Sander C Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983, 22:2577-2637. 10.1002/bip.360221211 6667333
58. The DSSP Software and Database http://swift.cmbi.ru.nl/gv/dssp/
59. Altschul SF Madden TL Schaffer AA Zhang J Zhang Z Miller W Lipman DJ Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res 1997, 25:3389-3402. 146917 9254694 10.1093/ nar/25.17.3389
60. Krieger N Lohmann V Bartenschlager R Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001, 75:4614-4624. 114214 11312331 10.1128/JVI.75.10.4614-4624.2001
61. Schechter I Berger A On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967, 27:157-162. 10.1016/ S0006-291X(67)80055-X 6035483